Chelation therapy for iron overload

被引：29

作者：

Barton J.C. ^{[1
]}

机构：

[1] Southern Iron Disorders Center, Birmingham, AL 35243

来源：

Current Gastroenterology Reports | 2007年 / 9卷 / 1期

关键词：

Sickle Cell Disease; Iron Overload; Hemochromatosis; Chelation Therapy; Deferasirox;

D O I：

10.1007/s11894-008-0024-9

中图分类号：

学科分类号：

摘要：

Iron overload is characterized by excessive iron deposition and consequent injury and dysfunction of the heart, liver, anterior pituitary, pancreas, and joints. Because physiologic mechanisms to excrete iron are very limited, patients with iron overload and its complications need safe, effective therapy that is compatible with their coexisting medical conditions. The availability of three licensed iron chelation drugs (one parenteral, two oral) and the development and clinical investigation of other oral chelators represent new opportunities to prevent or manage iron overload in patients with heritable types of severe anemia, such as β-thalassemia major and sickle cell disease, and for the formulation of alternatives to phlebotomy therapy for patients with iron overload associated with the HFE gene and other adult age-of-onset types of hemochromatosis, African iron overload, and African-American iron overload. Copyright © 2007 by Current Medicine Group LLC.

引用

页码：74 / 82

页数：8

共 50 条

[1]

Barton J.C., McDonnell S.M., Adams P.C., Et al., Management of hemochromatosis, Ann Intern Med, 129, pp. 932-939, (1998)

[2]

Anderson L.J., Wonke B., Prescott E., Et al., Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia, Lancet, 360, pp. 516-520, (2002)

[3]

Liu D.Y., Liu Z.D., Hider R.C., Oral iron chelators: Development and application, Best Pract Res Clin Haematol, 15, pp. 369-384, (2002)

[4]

Wanless I.R., Sweeney G., Dhillon A.P., Et al., Lack of progressive hepatic fibrosis during long-term therapy with deferiprone in subjects with transfusion-dependent beta-thalassemia, Blood, 100, pp. 1566-1569, (2002)

[5]

Barton J.C., Deferasirox Novartis, Curr Opin Investig Drugs, 6, pp. 327-335, (2005)

[6]

Piga A., Galanello R., Cappelini M.D., Et al., Phase II Study of oral chelator ICL670 in thalassaemia patients with transfusional iron overload: Efficacy, safety, pharmacokinetics (PK) and pharmacodynamics (PD) after 6 months of therapy, Blood, 100, (2002)

[7]

Cappellini M.D., Iron-chelating therapy with the new oral agent ICL670 (Exjade), Best Pract Res Clin Haematol, 18, pp. 289-298, (2005)

[8]

Kattamis A., Papassotiriou I., Palaiologou D., Et al., The effects of erythropoetic activity and iron burden on hepcidin expression in patients with thalassemia major, Haematologica, 91, pp. 809-812, (2006)

[9]

Anderson L.J., Holden S., Davis B., Et al., Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload, Eur Heart J, 22, pp. 2171-2179, (2001)

[10]

Anderson L.J., Westwood M.A., Prescott E., Et al., Development of thalassaemic iron overload cardiomyopathy despite low liver iron levels and meticulous compliance to desferrioxamine, Acta Haematol, 115, pp. 106-108, (2006)

← 1 2 3 4 5 →